Sarepta Therapeutics Inc

NASDAQ:SRPTUnited States

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Contact Information

Headquarters

215 1st St Ste 415CAMBRIDGE, MA, United States 02142-1213

Phone

617-274-4000

Fax

302-636-5454

Executives

Independent Chairwoman of the Board

M. Kathleen Behrens

President, Chief Executive Officer, Director

Douglas Ingram

Chief Financial Officer, Executive Vice President

Ian Estepan

Executive Vice President, Chief Scientific Officer, Head of R and D

Louise Rodino-Klapac

Executive Vice President, General Counsel, Corporate Secretary

Ryan Brown